<DOC>
	<DOCNO>NCT03006835</DOCNO>
	<brief_summary>This single-center , randomize , single-blind , investigator-initiated , pharmacological study parallel design . Patients non-ACS undergoing primary percutaneous coronary intervention randomize informed consent , 1:1:1:1 ratio follow treatment group : Group Α : Domestic Clopidogrel 300mg load dose PCI , follow 75mg per day . Group B : Domestic Clopidogrel 600mg load dose PCI , follow 75mg per day . Group B : Imported Clopidogrel 300mg load dose PCI , follow 75mg per day . Group D : Imported Clopidogrel 600mg load dose PCI , follow 75mg per day . Platelet inhibition ratio assessment thrombelastogram performed，2 hour load dose ( Day 0 ) ， 6 hour thrombelastogram ( Day 0 ) , 30 day thrombelastogram . Documentation major adverse cardiac event ( death , myocardial infarction , stroke , revascularization procedure PCI CABG ) serious adverse event ( bleed , adverse event ) perform Day 30 .</brief_summary>
	<brief_title>Different Dosage Domestic Imported Clopidogrel Platelet Inhibition Ratio Patients Undergoing PCI</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>1 . The patient schedule undergo nonurgent PCI 2 . The patient 18 75 year age ( inclusive ) willing comply protocol 3 . The patient legally acceptable representative able read give write informed consent sign informed consent form approve Investigator 's IRB/IEC 1 . Estimated measure weight &lt; 55 kg 2 . Acute nonSTsegment elevation myocardial infarction ( NSTEMI ) STsegment elevation myocardial infarction ( STEMI ) within 7 day prior PCI 3 . Uncontrolled hypertension time initial study drug administration define measure systolic blood pressure &gt; 190 mm Hg diastolic blood pressure &gt; 108 mm Hg 4 . Patient receive clopidogrel load dose ( ≥300 mg ) within 30 day prior randomization ; patient maintenance clopidogrel may enrol 5 . Administration thrombolytic agent , fondaparinux , oral anticoagulant ( e.g. , warfarin ) within 7 day prior PCI 6 . Estimated creatinine clearance ( e.g . CockcroftGault ) &lt; 45 mL/min 7 . Anemia hemoglobin level &lt; 10 g/dL 8 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) 9 . ALT and/or AST &gt; 2.5 x ULN indication clinically significant hepatic dysfunction 10 . Facial head trauma within last 30 day 11 . Intraocular hemorrhage within last 30 day 12 . Gastrointestinal bleeding within last 30 day 13 . Active bleeding , history bleed disorder know intracranial vascular malformation 14 . Known allergy contraindication aspirin , heparin , clopidogrel , contrast medium 15 . Participation investigational drug study within 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Clopidogrel ; Platelet Inhibition Ratio</keyword>
</DOC>